Details about Patricia M. Danzon

Access statistics for papers by Patricia M. Danzon.

Last updated 2024-04-05. Update your information in the RePEc Author Service.

Short-id: pda291

Working Papers

2012

1. Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
   See also Journal Article Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (12) (2015)

2011

2. Cross-National Evidence on Generic Pharmaceuticals: Pharmacy vs. Physician-Driven Markets
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (23)
3. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (6)
   See also Journal Article Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement, Health Economics, John Wiley & Sons, Ltd. (2015) View citations (12) (2015)
4. Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution?
   Occasional Paper, Office of Health Economics View citations (2)
5. Vaccine Supply: Effects Of Regulation And Competition
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (9)
   See also Journal Article Vaccine Supply: Effects of Regulation and Competition, International Journal of the Economics of Business, Taylor & Francis Journals (2011) View citations (9) (2011)

2008

6. Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (27)
   See also Chapter Effects of Regulation on Drug Launch and Pricing in Interdependent Markets, Advances in Health Economics and Health Services Research, Emerald Group Publishing Limited (2012) View citations (3) (2012)

2004

7. Mergers and Acquisitions in the Pharmaceutical and Biotech Industries
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (20)
   See also Journal Article Mergers and acquisitions in the pharmaceutical and biotech industries, Managerial and Decision Economics, John Wiley & Sons, Ltd. (2007) View citations (63) (2007)

2003

8. Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (31)
   See also Journal Article Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances, Journal of Health Economics, Elsevier (2005) View citations (67) (2005)
9. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand
   NBER Working Papers, National Bureau of Economic Research, Inc View citations (21)
   See also Chapter Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand, NBER Chapters, National Bureau of Economic Research, Inc (2004) View citations (44) (2004)
   Journal Article Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand, Forum for Health Economics & Policy, De Gruyter (2004) View citations (45) (2004)
10. The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (8)
    See also Journal Article The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s, Health Economics, John Wiley & Sons, Ltd. (2005) View citations (71) (2005)

2002

11. Biotech-Pharmaceutical Alliances as a Signal of Asset and Firm Quality
    NBER Working Papers, National Bureau of Economic Research, Inc View citations (22)
12. Pharmaceuticals: Access, Cost, Pricing, and Directions for the Future. 13th Annual Herbert Lourie Memorial Lecture on Health Policy
    Center for Policy Research Reports, Center for Policy Research, Maxwell School, Syracuse University

1990

13. Mandated Employment-Based Health Insurance: Incidence and Efficiency Effects
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
14. The Effects of Malpractice Litigation on Physicians' Fees and Incomes
    Working Papers, The University of Chicago Booth School of Business, George J. Stigler Center for the Study of the Economy and the State
    See also Journal Article The Effects of Malpractice Litigation on Physicians' Fees and Incomes, American Economic Review, American Economic Association (1990) View citations (8) (1990)

Journal Articles

2018

1. Differential Pricing of Pharmaceuticals: Theory, Evidence and Emerging Issues
   PharmacoEconomics, 2018, 36, (12), 1395-1405 View citations (13)

2015

2. Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition, and Procurement
   Health Economics, 2015, 24, (2), 238-252 View citations (12)
   See also Working Paper Pharmaceutical Pricing in Emerging Markets: Effects of Income, Competition and Procurement, NBER Working Papers (2011) View citations (6) (2011)
3. Pharmacy Benefit Management: Are Reporting Requirements Pro- or Anticompetitive?
   International Journal of the Economics of Business, 2015, 22, (2), 245-261
4. Value‐Based Differential Pricing: Efficient Prices for Drugs in a Global Context
   Health Economics, 2015, 24, (3), 294-301 View citations (12)
   See also Working Paper Value-Based Differential Pricing: Efficient Prices for Drugs in a Global Context, NBER Working Papers (2012) View citations (6) (2012)

2011

5. Vaccine Supply: Effects of Regulation and Competition
   International Journal of the Economics of Business, 2011, 18, (2), 239-271 View citations (9)
   See also Working Paper Vaccine Supply: Effects Of Regulation And Competition, NBER Working Papers (2011) View citations (9) (2011)

2008

6. "Crises" in medical malpractice insurance: Evidence of excessive price-cutting in the preceding soft market
   Journal of Banking & Finance, 2008, 32, (1), 157-169 View citations (10)

2007

7. At what price?
   Nature, 2007, 449, (7159), 176-179 View citations (3)
8. Dynamic competition in pharmaceuticals: cross-national evidence from new drug diffusion
   Managerial and Decision Economics, 2007, 28, (4-5), 231-250 View citations (6)
9. Mergers and acquisitions in the pharmaceutical and biotech industries
   Managerial and Decision Economics, 2007, 28, (4-5), 307-328 View citations (63)
   See also Working Paper Mergers and Acquisitions in the Pharmaceutical and Biotech Industries, NBER Working Papers (2004) View citations (20) (2004)

2005

10. Productivity in pharmaceutical-biotechnology R&D: the role of experience and alliances
    Journal of Health Economics, 2005, 24, (2), 317-339 View citations (67)
    See also Working Paper Productivity in Pharmaceutical Biotechnology R&D: The Role of Experience and Alliances, NBER Working Papers (2003) View citations (31) (2003)
11. The impact of price regulation on the launch delay of new drugs—evidence from twenty‐five major markets in the 1990s
    Health Economics, 2005, 14, (3), 269-292 View citations (71)
    See also Working Paper The Impact of Price Regulation on the Launch Delay of New Drugs - Evidence from Twenty-Five Major Markets in the 1990s, NBER Working Papers (2003) View citations (8) (2003)

2004

12. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand
    Forum for Health Economics & Policy, 2004, 7, (1), 56 View citations (45)
    See also Chapter Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand, NBER Chapters, 2004, 1-54 (2004) View citations (44) (2004)
    Working Paper Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand, NBER Working Papers (2003) View citations (21) (2003)

2002

13. A general model of the impact of absenteeism on employers and employees
    Health Economics, 2002, 11, (3), 221-231 View citations (44)
14. Health Insurance and the Growth in Pharmaceutical Expenditures
    Journal of Law and Economics, 2002, 45, (S2), 587-613 View citations (19)
15. Welfare effects of supplementary insurance: a comment
    Journal of Health Economics, 2002, 21, (5), 923-926 View citations (10)

2001

16. Comments on "The Assault on Managed Care: Vicarious Liability, ERISA Preemption, and Class Actions."
    The Journal of Legal Studies, 2001, 30, (2), 661-68
17. Worker's Compensation Rate Regulation: How Price Controls Increase Costs
    Journal of Law and Economics, 2001, 44, (1), 1-36 View citations (11)

2000

18. Cross-national price differences for pharmaceuticals: how large, and why?
    Journal of Health Economics, 2000, 19, (2), 159-195 View citations (98)
19. Does Regulation Drive out Competition in Pharmaceutical Markets?
    Journal of Law and Economics, 2000, 43, (2), 311-57 View citations (110)
20. Rate Regulation, Safety Incentives, and Loss Growth in Workers' Compensation Insurance
    The Journal of Business, 2000, 73, (4), 569-95 View citations (6)

1999

21. Medical negligence and the NHS: an economic analysis
    Health Economics, 1999, 8, (2), 93-101 View citations (8)

1997

22. Price Discrimination for Pharmaceuticals: Welfare Effects in the US and the EU
    International Journal of the Economics of Business, 1997, 4, (3), 301-322 View citations (39)
23. Price, Financial Quality, and Capital Flows in Insurance Markets
    Journal of Financial Intermediation, 1997, 6, (1), 3-38 View citations (107)
24. Tort Liability: A Minefield for Managed Care?
    The Journal of Legal Studies, 1997, 26, (2), 491-519 View citations (17)

1995

25. A measure of malpractice: Medical injury, malpractice litigation and patient compensation, by Paul C. Weiler et al. Cambridge, MA: Harvard University Press, 1993, 178 pp., $29.95 cloth
    Journal of Policy Analysis and Management, 1995, 14, (4), 636-638

1994

26. Health Care Reform
    Australian Economic Review, 1994, 27, (2), 81-88 View citations (8)
27. Price Cutting in Liability Insurance Markets
    The Journal of Business, 1994, 67, (4), 511-38 View citations (31)
28. The Swedish patient compensation system: Myths and realities
    International Review of Law and Economics, 1994, 14, (4), 453-466 View citations (3)
29. Tort Reform: The Case of Medical Malpractice
    Oxford Review of Economic Policy, 1994, 10, (1), 84-98 View citations (2)

1993

30. Holdouts, Externalities, and the Single Owner: One More Salute to Ronald Coase: Comment
    Journal of Law and Economics, 1993, 36, (1), 587-94
31. The Economic Implications of Public Disability Insurance in the United States
    Journal of Labor Economics, 1993, 11, (1), S170-200 View citations (13)

1991

32. Liability for Medical Malpractice
    Journal of Economic Perspectives, 1991, 5, (3), 51-69 View citations (30)
    See also Chapter Liability for medical malpractice, Handbook of Health Economics, 2000, 1, 1339-1404 (2000) View citations (60) (2000)

1990

33. Alternative Liability Regimes for Medical Injuries
    The Geneva Papers on Risk and Insurance - Issues and Practice, 1990, 15, (1), 3-21 View citations (4)
34. The Effects of Malpractice Litigation on Physicians' Fees and Incomes
    American Economic Review, 1990, 80, (2), 122-27 View citations (8)
    See also Working Paper The Effects of Malpractice Litigation on Physicians' Fees and Incomes, Working Papers (1990) (1990)

1988

35. The Political Economy of Workers' Compensation: Lessons for Product Liability
    American Economic Review, 1988, 78, (2), 305-10 View citations (3)

1985

36. Liability and liability insurance for medical malpractice
    Journal of Health Economics, 1985, 4, (4), 309-331 View citations (22)

1984

37. Separation of the redistributive and allocative functions of government: A public choice perspective
    Journal of Public Economics, 1984, 24, (3), 373-380 View citations (5)
38. The Frequency and Severity of Medical Malpractice Claims
    Journal of Law and Economics, 1984, 27, (1), 115-48 View citations (36)

1983

39. Contingent Fees for Personal Injury Litigation
    Bell Journal of Economics, 1983, 14, (1), 213-224 View citations (54)
40. Regulatory policy and practices: Regulating better and regulating less, by Fred Thomson and L.R. Jones. New York: Praeger Publishers, 1982, 253 pp. Price: $29.95
    Journal of Policy Analysis and Management, 1983, 3, (1), 154-154
41. Risk by choice: Regulating health and safety in the workplace, by W. Kip Viscusi. Cambridge, MA: Harvard University Press, 1983, 200 pp. Price: $18.50
    Journal of Policy Analysis and Management, 1983, 3, (1), 154-155 View citations (1)

1982

42. Hospital `profits': The effects of reimbursement policies
    Journal of Health Economics, 1982, 1, (1), 29-52 View citations (16)
43. Regulation and its reform, by Stephen Breyer. Cambridge, MA: Harvard University Press, 1982, 472 pp. Price: $25.00
    Journal of Policy Analysis and Management, 1982, 2, (1), 141-141

Edited books

2012

1. The Oxford Handbook of the Economics of the Biopharmaceutical Industry
   OUP Catalogue, Oxford University Press View citations (18)

Chapters

2014

1. Regulation of the Pharmaceutical-Biotechnology Industry
   A chapter in Economic Regulation and Its Reform: What Have We Learned?, 2014, pp 407-484 View citations (4)

2012

2. Effects of Regulation on Drug Launch and Pricing in Interdependent Markets
   A chapter in The Economics of Medical Technology, 2012, pp 35-71 View citations (3)
   See also Working Paper Effects of Regulation on Drug Launch and Pricing in Interdependent Markets, National Bureau of Economic Research, Inc (2008) View citations (27) (2008)
3. Regulation of the Biopharmaceutical Industry
   Chapter 14 in Regulation and Economics, 2012

2004

4. Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand
   A chapter in Frontiers in Health Policy Research, Volume 7, 2004, pp 1-54 View citations (44)
   See also Journal Article Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands, and New Zealand, De Gruyter (2004) View citations (45) (2004)
   Working Paper Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, the Netherlands and New Zealand, National Bureau of Economic Research, Inc (2003) View citations (21) (2003)

2000

5. Liability for medical malpractice
   Chapter 26 in Handbook of Health Economics, 2000, vol. 1, pp 1339-1404 View citations (60)
   See also Journal Article Liability for Medical Malpractice, American Economic Association (1991) View citations (30) (1991)

1999

6. The Effects of Price Regulation on Productivity in Pharmaceuticals
   A chapter in International and Interarea Comparisons of Income, Output, and Prices, 1999, pp 371-418 View citations (2)